Conmed vs TransMedics
CNMD and TMDX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNMD and TMDX compare
TransMedics is the larger company, worth 2.1 times as much as Conmed ($3.2B against $1.5B).
On earnings, Conmed is cheaper: it trades at 20.9× trailing earnings, against 25.0× for TransMedics.
TransMedics grew revenue faster over the last twelve months (28.5% versus 1.6% for Conmed).
TransMedics keeps more of each dollar of sales as profit, with a net margin of 19.9% compared with 5.4% at Conmed.
TransMedics scores higher on the StockData Score (15 against 14 for Conmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNMD | TMDX |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $3.2B |
| Share price | $50.59 | $91.38 |
| Change, 1 year | 16.1% | −23.3% |
| Change, 5 years | −64.4% | 301% |
| Beta (5Y) | 0.94 | 1.34 |
| Employees | 3,900 | 898 |
| StockData Score | ||
| Total score | 14 | 15 (better) |
| Valuation score | 6 (better) | 5 |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 20.9× (better) | 25.0× |
| P/S | 1.1× (better) | 4.4× |
| P/B | 1.4× (better) | 5.8× |
| EV/EBITDA | 16.8× (better) | 21.5× |
| P/FCF | 11.4× (better) | 70.9× |
| FCF yield | 8.8% (better) | 1.4% |
| Fair value | $65.95 | $129.52 |
| Margin of safety | 23.3% | 29.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.6% | 28.5% (better) |
| Revenue growth, 5Y average | 9.8% | 88.2% (better) |
| Net income growth (TTM) | 14.6% | 57.4% (better) |
| EPS growth (TTM) | 18.0% | 47.8% (better) |
| EPS growth, 5Y average | 36.4% | – |
| Profitability | ||
| Gross margin | 57.6% | 58.6% (better) |
| Operating margin | 9.9% | 11.9% (better) |
| Net margin | 5.4% | 19.9% (better) |
| FCF margin | 9.7% (better) | 6.1% |
| Return on equity | 7.1% | 31.9% (better) |
| Return on invested capital | 5.2% | 2622% (better) |
| Financial health | ||
| Debt / equity | 0.77 | 0.10 (better) |
| Net debt / EBITDA | 5.66 (better) | −3.45 |
| Interest coverage | 4.1× (better) | 3.5× |
| Current ratio | 1.49 | 4.53 (better) |
| Altman Z-score | 2.02 | 2.84 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 8.4% | – |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | −5.6% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 114% | 100% |
| Held by insiders | 0.47% | 3.9% |
| Insider net buying, 12 months | $0 (better) | −$4.2M |
| Short interest, % of float | 6.3% | 26.6% |
Go deeper
- CNMD stock overview
- CNMD income statement
- CNMD valuation and score
- TMDX stock overview
- TMDX income statement
- TMDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.